Aequus Pharmaceuticals (AQSZF)

[BioSpecialist]

you forget that they are very close to acquire many new revenue generating products which will drive the company to profitability (see chart below).Another big milestone is the US-NDA submission for AQS1301 likely before year end and the NDS submission for trokendi ER by mid this year . We are talking about a company which is valued at laughable $11 Million you will not find a cheaper stock than this one. Any good news like the product acqusition and this stock is back over 0.30 and higher .